Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 566 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol administration; Placebo administration Clear all
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence

NCT00142818
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders
Interventions
Naltrexone, Modafinil, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 21, 2026, 4:11 PM EDT
Terminated Phase 2 Interventional Results available

Propranolol in Treating Hypoglycemia Unawareness

NCT03161964
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule
Drug
Lead sponsor
Anu Sharma
Other
Eligibility
21 Years to 59 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

NCT07053774
View directory record Official record
Conditions
Pain, Acute
Interventions
Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 3 Interventional

Medication and Counseling for Controlled Drinking (Project SMART)

NCT00444418
View directory record Official record
Conditions
Alcohol-related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse
Interventions
Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy
Drug · Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin

NCT01916941
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Prazosin, Placebo
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 1 Interventional

Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder

NCT02407340
View directory record Official record
Conditions
Alcoholism, Alcohol Related Disorders
Interventions
oxytocin, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 21, 2026, 4:11 PM EDT
Recruiting Not applicable Interventional

Pro-2-Cool Pivotal Trial II

NCT06929923
View directory record Official record
Conditions
Concussion, Mild
Interventions
Pro2Cool Device, Sham Cooling Garment Device
Device
Lead sponsor
TecTraum Inc.
Industry
Eligibility
13 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Ann Arbor, Michigan • Akron, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 4:11 PM EDT
Recruiting Phase 3 Interventional

Optimizing Treatment of Adhesive Small Bowel Obstruction

NCT06182319
View directory record Official record
Conditions
Adhesive Small Bowel Obstruction
Interventions
Gastrografin, Saline, SBO Treatment Without NG Tubes
Drug · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 21, 2026, 4:11 PM EDT
Terminated Phase 1Phase 2 Interventional

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

NCT01025648
View directory record Official record
Conditions
Asthma
Interventions
E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Jose, California • Stockton, California
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

NCT03155893
View directory record Official record
Conditions
Healthy
Interventions
ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 21, 2026, 4:11 PM EDT
Recruiting Phase 1 Interventional

Spironolactone in Alcohol Use Disorder (SAUD)

NCT05807139
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Spironolactone
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
74
States / cities
Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 21, 2026, 4:11 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

NCT01795235
View directory record Official record
Conditions
Healthy
Interventions
Saline, Glucagon, Placebo, Atenolol
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence

NCT00981617
View directory record Official record
Conditions
Alcohol Dependence
Interventions
ALKS33 (RDC-0313) (1 mg), ALKS33 (RDC-0313) (2.5 mg), ALKS33 (RDC-0313) (10 mg), Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
27
States / cities
Tucson, Arizona • Cerritos, California • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

NCT01576718
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 21, 2026, 4:11 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

NCT04130438
View directory record Official record
Conditions
Myocardial Bridging
Interventions
Nebivolol, Diltiazem, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

New Treatment for Alcohol and Nicotine Dependence

NCT01182766
View directory record Official record
Conditions
Alcohol Dependence, Nicotine Dependence
Interventions
Low-Dose Topiramate, Placebo, High-Dose Topiramate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
La Jolla, California • Houston, Texas • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

NCT00249405
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Citalopram + MI, Placebo + MI
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 21, 2026, 4:11 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Alcohol and Bariatric Surgery

NCT02766322
View directory record Official record
Conditions
Obesity
Interventions
Oral Alcohol challenge test Alcohol visit first, Oral Alcohol challenge test Placebo visit first, Intravenous Alcohol Challenge Test (Clamp), Intravenous Alcohol Self-administration Test
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 4:11 PM EDT
Terminated Phase 4 Interventional Results available

Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder

NCT00648375
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Propanolol, Placebo, Cognitive therapy workbook
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Phase 2 Interventional

CBD for the Treatment of Alcohol Use Disorder

NCT04873453
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 21, 2026, 4:11 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Alcohol and Mood on Attention

NCT04276779
View directory record Official record
Conditions
Suicidal Ideas
Interventions
Alcohol administration, Placebo administration, Positive mood induction, Negative mood induction
Other · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 4:11 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands

NCT00973856
View directory record Official record
Conditions
Papillomavirus Infections, Warts, Condylomata Acuminata, Epidermodysplasia Verruciformis
Interventions
PURELL VF481, Placebo Solution
Other
Lead sponsor
Cleveland Clinic Akron General
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 21, 2026, 4:11 PM EDT